ANTHIM® (obiltoxaximab)
ANTHIM® (obiltoxaximab) is indicated in adult and pediatric patients for the treatment of inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs. ANTHIM is indicated for prophylaxis of inhalational anthrax due to B. anthracis when alternative therapies are not available or are not appropriate.
Availability: Commercially Available
| Manufacturer |
| Elusys Therapeutics, Inc. |
| Product Name |
| ANTHIM® (obiltoxaximab) |
| Detection Category |
| Biological |
| Detection Method |
| Medical Countermeasure; |
| Application |
| Personal Protective Equipment; |
| Equipment Type |
| PPE |
| Product Synopsis |
| ANTHIM® (obiltoxaximab) is indicated in adult and pediatric patients for the treatment of inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs. ANTHIM is indicated for prophylaxis of inhalational anthrax due to B. anthracis when alternative therapies are not available or are not appropriate. |
| Availability |
| Commercially Available |
| Technology Readiness Level (TRL) |
| 9 |
| Market Entry Date |
| 2016 |
| User Feedback Sources |
| Indifferent/No user feedback |
| Weight |
| <1 lb. |
| Power Requirements |
| None |
| Transportability |
| Pocket Size |
| Live Agent Tested |
| Yes; B. anthracis (anthrax) |
| Operating Time |
| Immediate post-exposure use |
| Standards Met |
| FDA |
| Training Required |
| <1 hour training |
| Manuals Available |
| Yes |
